Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

被引：0
|
作者：
Dhanashree Ratra
Krishnakanta Roy
Sneha Giridhar
Sushant Madaan
机构：
[1] Medical Research Foundation,Department of Vitreoretinal Diseases
[2] Sankara Nethralaya,undefined
来源：
Ophthalmology and Therapy | 2022年 / 11卷
关键词：
Anti VEGF; Biosimilar; Comparison with bevacizumab; DME; nAMD; Ranibizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：135 / 149
页数：14
相关论文
共 50 条
  • [21] Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    V Chong
    Eye, 2016, 30 : 270 - 286
  • [22] Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    Chong, V.
    EYE, 2016, 30 (02) : 270 - 286
  • [23] Real-world outcomes of Ranibizumab treatment for Diabetic Macular Oedema
    Patrao, Namritha Valerie
    Antao, Sheelah
    Sim, Dawn A.
    Sivaprasad, Sobha
    Andrews, Richard
    Hamilton, Robin
    Egan, Catherine A.
    Tufail, Adnan
    Hykin, Philip G.
    Rajendram, Ranjan
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [24] Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
    Sermsiri Sangroongruangsri
    Usa Chaikledkaew
    Suthasinee Kumluang
    Olivia Wu
    Claudia Geue
    Tanapat Ratanapakorn
    Pattara Leelahavarong
    Lily Ingsrisawang
    Paisan Ruamviboonsuk
    Wongsiri Taweebanjongsin
    Janejit Choovuthayakorn
    Apichart Singalavanija
    Prut Hanutsaha
    Kittisak Kulvichit
    Thitiporn Ratanapojnard
    Warapat Wongsawad
    Yot Teerawattananon
    Clinical Drug Investigation, 2019, 39 : 115 - 115
  • [25] Comparison of anti-angiogenic effect in vitro between ranibizumab and bevacizumab
    Souto, Alexandre Cupello
    Maricato, Juliana Terzi
    Andrade Denapoli, Priscila Martins
    Ferraz Sallum, Juliana Maria
    Han, Sang Won
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2011, 74 (05) : 338 - 342
  • [26] Ranibizumab Pre-Filled Syringe Versus Ranibizumab Vial: Syringe Preparation Time in Real-World Clinical Practice
    Souied, Eric
    Nghiem-Buffet, Sylvia
    Leteneux, Claudia
    Bayer, Sascha
    Derveloy, Audrey
    Sagkriotis, Alexandros
    Becker, Guido
    Cohen, Salomon-Yves
    OPHTHALMOLOGICA, 2014, 232 : 70 - 70
  • [27] Erratum: Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    V Chong
    Eye, 2016, 30 : 1526 - 1526
  • [28] Real-World Canadian Study to Compare the Syringe Preparation Time for Ranibizumab Prefilled Syringe versus Ranibizumab and Aflibercept Vial
    Giunta, Michel
    Lalonde, Laurent
    Cordahi, Ghassan
    Saurel, Patrick
    Scarino, Andrea
    OPHTHALMOLOGICA, 2016, 236 : 7 - 7
  • [29] Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
    Erol, Muhammet Kazim
    Coban, Deniz Turgut
    Sari, Esin Sogutlu
    Bilgin, Ahmet Burak
    Dogan, Berna
    Ozdemir, Ozdemir
    Tunay, Zuhal Ozen
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2015, 78 (06) : 340 - 343
  • [30] Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
    Ceylan, Osman Melih
    Dikci, Seyhan
    Genc, Oguzhan
    Yilmaz, Turgut
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2016, 79 (04) : 279 - 279
12345